Trial Profile
A cross-sectional study evaluating impact of the modality on patient treatment and survival of 68Ga-DOTATATE PET/CT Imaging in patients with confirmed or suspected neuroendocrine tumors
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jun 2016
Price :
$35
*
At a glance
- Drugs Gallium 68-DOTATATE (Primary)
- Indications Neuroendocrine tumours
- Focus Diagnostic use
- 10 Jun 2016 New trial record